February 19, 2018 — A late-breaking analysis of the landmark COMPASS study was presented at the 2018 International ...
Pharmaceuticals
This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.
February 13, 2018 — Abbott announced the first patient has been enrolled in a clinical trial evaluating 28 days of dual ...
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the National ...
January 22, 2018 — Baxter International Inc. announced the U.S. Food and Drug Administration (FDA) approval of ...
January 19, 2018 — The U.S. Food and Drug Administration (FDA) announced that International Laboratories LLC is ...
January 16, 2018 — American College of Cardiology (ACC) Chief Executive Officer Shalom “Shal” Jacobovitz will be leaving ...
December 12, 2017 — Mayo Clinic researchers have shown a link between which type of oral anticoagulant a patient takes ...
November 16, 2017 — Bristol-Myers Squibb Company and Pfizer Inc. released real-world data (RWD) of outcomes associated ...
November 10, 2017 — Moderna Therapeutics announced a new license and collaboration with AstraZeneca to co-develop and co ...
November 6, 2017 —  The first trial to evaluate the safety of dual antiplatelet therapy (DAPT) for less than 12 months ...
November 6, 2017 — Elderly patients undergoing percutaneous coronary intervention (PCI) often receive bare-metal stents ...
November 3, 2017 — A ten-year decline in the blood cholesterol of heart attack patients in Malaysia suggests statins are ...
November 1, 2017 — OrbusNeich reported results from the REDUCE trial in the Late-Breaking Clinical Trial session at the ...
October 27, 2017 — CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of ...
October 24, 2017 — Roche and Ncardia have reached a broad licensing agreement whereby Roche and its affiliate companies ...